Investing.com - Heron Therapeuti reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Heron Therapeuti announced...
Heron Therapeutics (NASDAQ:HRTX) reported Q1 EPS of ($0.63), $0.15 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $22.4 million versus the consensus...
As the earnings season comes to an end, the focus is back on pipeline updates from biotech players. While the bigwigs did not come out with much updates, pipeline and regulatory...
Heron Therapeutics, Inc. (NASDAQ:HRTX) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more...
Heron Therapeutics, Inc. (NASDAQ:HRTX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover...
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.